Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: J Viral Hepat. 2015 Mar 6;22(11):936–947. doi: 10.1111/jvh.12398

Figure 2. Standardized cumulative incidences (i.e., risks) of hip fracture, based on competing risk regression analyses.

Figure 2

Figure 2

Figure 2

Estimates of the cumulative incidence of hip fracture are reported for each group. Estimates are standardized to the characteristics of dually-treated HIV/hepatitis B virus coinfected patients.

(A) Standardized cumulative incidences (i.e., risks) of hip fracture between dually-treated HIV/hepatitis B virus-coinfected (denoted by black line) and treated hepatitis B virus-monoinfected patients (denoted by gray line). Coinfected patients in this figure represent only a subset of all coinfected patients. Remaining coinfected patients could not be matched to the hepatitis B virus-monoinfected patients because the characteristics of the two groups differed so markedly. Standardized for age and sex after matching.

(B) Standardized cumulative incidences (i.e., risks) of hip fracture between dually-treated HIV/hepatitis B virus-coinfected (denoted by black line) and antiretroviral-treated HIV-monoinfected patients (denoted by gray line). Standardized using age, sex, and tenofovir use after matching.

(C) Standardized cumulative incidences (i.e., risks) of hip fracture between dually-treated HIV/hepatitis B virus-coinfected (denoted by black line) and HIV/hepatitis B virus-uninfected patients (denoted by gray line). Standardized for age and sex after matching.